BriaCell Therapeutics plans to consolidate its common shares at a 10:1 ratio to maintain Nasdaq listing requirements, effective August 25, 2025.

BriaCell reported promising Phase 2 survival data for Bria-IMT immunotherapy in metastatic breast cancer, showing improved median overall survival compared to Trodelvy and single-agent chemotherapy across triple-negative and hormone receptor-positive breast cancer subtypes.

The article discusses the rise in cancer incidence and the need for better treatments, as well as the potential impact of budget reductions and new tariffs on innovation. Several oncology companies, including Oncolytics Biotech, Sutro Biopharma, BriaCell Therapeutics, and Tempus AI, have reported notable updates in 2025.

BriaCell Therapeutics Corp. announced the pricing of a $13.8 million public offering, with each unit consisting of one common share (or pre-funded warrant) and one warrant. The company plans to use the proceeds for working capital, general corporate purposes, and advancing its business objectives.

BriaCell Therapeutics, a clinical-stage biotechnology company, will present three posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The posters will cover topics related to their cancer immunotherapy pipeline, including Bria-ABC1, Bria-IMT, and Bria-OTS+.